Germany· DE-A57-e028e1cb5ee318c5
Berberis/Uterus Comp.
A medicinal product, registered in Germany by Wala Heilmittel Gmbh.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
The record
At a glance
EMA Article 57 (European Union)- Manufacturer
- Wala Heilmittel Gmbh
- Country
- Germany (DE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d049b623-2559-4dc1-bffe-aa1add4ea312 GET /v1/drugs/d049b623-2559-4dc1-bffe-aa1add4ea312?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Sublingual Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Berberis Vulgaris E Radice Ferm 33d Ø (Hab, Vs. 33d), Berberis Vulgaris Ex Herba Ferm 33c Ø (Hab, Vs. 33c), Granit Dil. D9 (Hab, Vs. 6), Magnesium Sulfuricum Dil. D5 Aquos. (Hab, Vs. 5b), Urtica Urens Ex Herba Ferm 33c Dil. D2 (Hab, Vs. 33c), Uterus Bovis Gl Dil. D5 (Hab, Vs. 41c), Viscum Album (Mali) E Planta Tota Ferm 34i Dil. D3 (Hab, Vs. 34i), Oxalis Acetosella E Planta Tota Ferm 34b Dil. D2 (Hab, Vs. 34b), Ovaria Bovis Gl Dil. D5 (Hab, Vs. 41a)",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about Berberis/Uterus.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.